Side-by-side · Research reference
CortagenvsPT-141
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED11/35 cited
BFDA-ApprovedHUMAN-REVIEWED13/41 cited
Cortagen
Bioregulatory Tetrapeptide · Khavinson-School
Injectable · Animal models
PT-141
MC4R Agonist · FDA-Approved (HSDD)
SQ · Abdomen / thigh · ≥45 min before sex
01Mechanism of Action
Parameter
Cortagen
PT-141
Primary target
Cerebral cortex tissue — molecular targets under investigation
Melanocortin-4 receptor (MC4R) in hypothalamusSimerly 2023VYLEESI (bremelanotide injecti 2019
Pathway
Antioxidant pathway modulation — suppression of LPO cascade, reduction of protein oxidative modificationKozina 2007
MC4R agonism in paraventricular nucleus → autonomic + neuroendocrine sexual arousal pathwaysSimerly 2023
Downstream effect
Decreased lipid peroxidation products, reduced oxidative protein damage, altered gene expression in cardiac tissueKozina 2007Anisimov 2004
Increased sexual desire and arousal; central rather than peripheral mechanismClayton 2015
Feedback intact?
—
—
Origin
Synthetic tetrapeptide derived from amino acid analysis of natural brain cortex peptide preparation CortexinAnisimov 2004
Cyclic 7-AA peptide derived from α-MSH (agonist Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-OH cyclic)VYLEESI (bremelanotide injecti 2019
Antibody development
—
—
02Dosage Protocols
Parameter
Cortagen
PT-141
Animal model dose (rat)
Injection protocol (dose not specified in abstracts)
Multiple injections over study period.
—
Avian model dose (chicken)
40-day injection courseKuznik 2008
Compared to epithalon in hypophysectomized and aged birds.
—
Human peripheral nerve study
Therapeutic course (protocol details not provided)
Posttraumatic recovery context — reference cited but not detailed.
—
Evidence basis
Animal mechanistic studies
FDA-approved (HSDD pre-menopausal women)VYLEESI (bremelanotide injecti 2019Clayton 2015
Route
Injectable (inferred from animal protocols)
—
Standard dose
—
1.75 mg SQVYLEESI (bremelanotide injecti 2019
Single dose ≥45 min before anticipated sexual activity. Max 1 dose / 24 hr.
Frequency
—
PRN, max 8 doses / month
Lower / starter dose
—
1 mg (off-label)
Duration
—
PRN; reassess if no benefit after 8 doses
Reconstitution
—
Pre-filled commercial pen (Vyleesi). Research vial: bacteriostatic water.
Timing
—
≥45 min before sexual activity
04Side Effects & Safety
Parameter
Cortagen
PT-141
Antioxidant suppression
Suppression of antioxidant activity noted alongside LPO reductionKozina 2007
Mechanism unclear — possible homeostatic adaptation.
—
Immune/hemostasis effects
No effect on immunity or hemostasis parameters in avian hypophysectomy model (unlike epithalon)Kuznik 2008
Epithalon reversed deficits; cortagen did not.
—
Human safety data
No adverse events reported in peripheral nerve recovery context
Limited detail in available abstracts.
—
Flushing
—
Common, transient
Injection site reaction
—
Erythema, mild pain
Headache
—
Common
Hyperpigmentation (focal)
—
Rare focal skin darkening; reversible after discontinuationVYLEESI (bremelanotide injecti 2019
Hypertension (transient)
—
Mean ↑6 mmHg systolic peaking ~4 h post-dose; resolves within 12 hVYLEESI (bremelanotide injecti 2019
Pregnancy / OB
—
Contraindicated
Cardiovascular disease
—
Use caution; transient BP rise
Absolute Contraindications
Cortagen
—PT-141
- ·Uncontrolled hypertension
- ·Known cardiovascular disease (caution)
- ·Pregnancy
Relative Contraindications
Cortagen
—PT-141
- ·Pre-existing hyperpigmentation disorders
- ·MC4R-pathway-dependent psychiatric conditions
05Administration Protocol
Parameter
Cortagen
PT-141
1. Preparation
Reconstitute lyophilised peptide with bacteriostatic water per supplier protocol. Exact volumes depend on concentration supplied.
Vyleesi: pre-filled auto-injector. Research vial: 2 mL bacteriostatic water per 10 mg → 5 mg/mL.
2. Injection site
Subcutaneous injection typical for bioregulatory peptides — abdomen or thigh. Rotate sites.
SQ — abdomen or thigh.
3. Timing
Animal protocols used repeated dosing over weeks. Human timing not established — evening administration common in Khavinson tradition.
≥45 min before sexual activity for peak effect. Effect persists ~6–8 h.
4. Storage
Lyophilised: refrigerate or freeze per supplier. Reconstituted: refrigerate 2–8 °C, use within guideline window.
Vyleesi: room temp ≤30 °C. Research vial: refrigerate after reconstitution.
5. Needle
—
Auto-injector (Vyleesi) or 29–31G, 4–8 mm insulin syringe.